Daiichi Sankyo Co Ltd 2014 IR
The report outlines the Daiichi Sankyo Group's strategy for sustainable corporate value improvement by integrating economic value cycles with responsible corporate activities. Key highlights from fiscal 2013 include global marketing applications for the anticoagulant edoxaban and the strategic merger of Ranbaxy with Sun Pharma. The company also advanced open innovation through the TaNeDS programme and the establishment of Venture Science Laboratories. Additionally, Daiichi Sankyo expanded access to medical services in developing countries through mobile healthcare clinics and technical cooperation for vaccine production.
Company: Daiichi Sankyo Co Ltd
Sector: Health Care
Country: Japan
Year: 2014
Type: IR
Pages: 94
Daiichi Sankyo Co Ltd
Value Report
The report outlines the Daiichi Sankyo Group's strategy for sustainable corporate value improvement by integrating economic value cycles with responsible corporate activities. Key highlights from fiscal 2013 include global marketing applications for the anticoagulant edoxaban and the strategic merger of Ranbaxy with Sun Pharma. The company also advanced open innovation through the TaNeDS programme and the establishment of Venture Science Laboratories. Additionally, Daiichi Sankyo expanded access to medical services in developing countries through mobile healthcare clinics and technical cooperation for vaccine production.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2014
Reporting Period
Apr 1, 2013 - Mar 31, 2014
Fiscal Year
2013
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Employees